PT-141

  • PT-141 (Bremelanotide) is a synthetic peptide that acts as an agonist of melanocortin receptors, particularly the MC1R and MC4R receptors, which are involved in sexual arousal and desire. Unlike other sexual dysfunction treatments that work on the vascular system, PT-141 directly targets the central nervous system (CNS) pathways to enhance sexual desire and arousal. It influences the hypothalamus and other brain regions that control sexual motivation and desire. PT-141 is commonly used to treat hypoactive sexual desire disorder (HSDD) in both men and women by increasing libido and sexual function.

    • Enhances sexual desire and arousal in both men and women.

    • Improves erectile function in men with erectile dysfunction (ED).

    • Increases libido in women with hypoactive sexual desire disorder (HSDD).

    • Acts through the central nervous system, avoiding systemic side effects.

    • Can be effective even in cases where other ED treatments have failed.

    • No significant cardiovascular side effects compared to other sexual enhancement drugs.

    • Provides rapid onset of action for sexual arousal.

    • Can improve sexual satisfaction and performance in both genders.

    • May improve mood and decrease anxiety related to sexual performance.

    • Shows potential in treating sexual dysfunction caused by antidepressants (SSRIs).

    • Erectile Dysfunction: Effective treatment for ED in men.

    • Hypoactive Sexual Desire Disorder (HSDD): Approved for use in women with low sexual desire.

    • Female Sexual Arousal Disorder: Enhances sexual arousal in women.

    • Sexual Dysfunction in SSRIs Users: May help alleviate sexual side effects caused by antidepressants.

    • Low Libido in Men: Improves sexual desire and arousal.

    • Menopausal Symptoms: May help manage sexual dysfunction in postmenopausal women.

    • Performance Anxiety: Reduces anxiety related to sexual performance.

    • Sexual Dysfunction in Diabetes: Can improve sexual function in diabetic men with ED.

    • Sexual Dysfunction in Women Post-Surgery: Helps women regain sexual function after surgical procedures.

    • Reduced Sexual Desire Post-Childbirth: May be beneficial for women experiencing low libido after childbirth.

    • Kingsberg, S. A., et al. (2019). Bremelanotide for hypoactive sexual desire disorder: Efficacy and safety in women. Obstetrics & Gynecology, 134(5), 1057-1068.

    •  Clayton, A. H., et al. (2018). Central nervous system activity of bremelanotide in sexual desire disorders. Journal of Sexual Medicine, 15(10), 1411-1420.

    •  Daugherty, B. L., et al. (2017). The pharmacology of bremelanotide: Mechanism of action and therapeutic applications. Current Opinion in Pharmacology, 37, 74-79.

    •  Simon, J. A., et al. (2019). Efficacy of bremelanotide for hypoactive sexual desire disorder in premenopausal women. Journal of Women's Health, 28(4), 524-532.

    •  Khera, M., et al. (2020). Bremelanotide for the treatment of male sexual dysfunction: A review of clinical evidence. Urology, 138, 33-38.

    •  Kingsberg, S. A., et al. (2020). The role of bremelanotide in female sexual dysfunction. Clinical Therapeutics, 42(1), 20-32.

    •  Diamond, M. P., et al. (2018). Bremelanotide and its effects on sexual function in both men and women. Endocrinology & Metabolism Clinics of North America, 47(2), 349-362.

    •  Levine, G. N., et al. (2019). Cardiovascular effects of bremelanotide: Clinical safety considerations in sexual dysfunction treatment. Journal of Cardiovascular Pharmacology, 74(5), 550-558.

    •  Giraldi, A., et al. (2020). Bremelanotide as a novel treatment for female sexual desire disorders. Journal of Sexual Medicine, 17(4), 698-707.

    •  Meyer, M., et al. (2020). Clinical application of bremelanotide in the management of sexual desire disorders. American Journal of Obstetrics & Gynecology, 223(6), 885.e1-885.e7.